Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

"We know that clinical trials have recently been investigating the combination of teclistamab and daratumumab for multiple myeloma treatment," said SU2C ... getting rid of this amyloid buildup, which ...

During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello, ladies and gentlemen, and welcome to the Autolus ...

As the second leading cause of cancer deaths and the fifth most common cancer ... The global prevalence of blood cancers, including leukemia, lymphoma, and multiple myeloma, continues to rise. Blood ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

3 For the 24,000 people living with multiple myeloma in the UK ... during the clinical study that might further embed caution or cause them to have a negative experience. These could be issues ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...